Drug Profile
Influenza virus vaccine live intranasal (quadrivalent) - AstraZeneca
Alternative Names: Fluenz Tetra; Flumist; FluMist Quadrivalent; Influenza vaccine live-intranasal (quadrivalent) - AstraZeneca; MEDI-3250; MEDI-8662; Q-LAIV Flu Vac; Q-LAIV Flu Vaccination; Q-LAIV-AstraZeneca; Q-LAIV-BFS-AstraZeneca; Q/LAIV; Q/LAIV-AstraZeneca; Q/LAIV-BFS-AstraZeneca; Quadrivalent live attenuated influenza vaccine - AstraZeneca; Quadrivalent live attenuated influenza virus vaccine - AstraZeneca; VN-0107Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca; Japan Vaccine
- Class Influenza virus vaccines live
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 24 Oct 2023 FDA assigns PDUFA action date of 31/03/2024 (first quarter of 2024)for self- or caregiver-administered option for Influenza virus vaccine live intranasal for the prevention of Influenza virus infections
- 24 Oct 2023 AstraZeneca plans to launch the self- or caregiver-administered option for Influenza virus vaccine in the US for the 2024/2025 flu season
- 24 Oct 2023 The US FDA accepts sBLA for the approval of a self- or caregiver-administered option for intranasal influenza virus vaccine live intranasal for Influenza virus infections for review